Myelodysplastic Syndromes × Azacitidine × Lymphoid × Clear all Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 Recruiting
30 enrolled
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
Phase 1 Completed
38 enrolled 14 charts
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
17 enrolled 15 charts
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Phase 1 Terminated
21 enrolled
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
94 enrolled
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Phase 1 Terminated
24 enrolled 21 charts
Study of INCB053914 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
97 enrolled 40 charts
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
Phase 2 Completed
17 enrolled 12 charts
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Phase 1 Completed
89 enrolled
RACE
Phase 1 Completed
31 enrolled
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Phase 1 Terminated
2 enrolled
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Phase 1 Completed
72 enrolled
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
Phase 2 Completed